Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) Shares Outstanding (Diluted Average) (2020 - 2024)

Immuneering (IMRX) has 5 years of Shares Outstanding (Diluted Average) data on record, last reported at $29.8 million in Q3 2024.

  • For Q3 2024, Shares Outstanding (Diluted Average) rose 6.09% year-over-year to $29.8 million; the TTM value through Sep 2024 reached $29.8 million, up 6.09%, while the annual FY2023 figure was $28.4 million, 7.69% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $29.8 million in Q3 2024 per IMRX's latest filing, up from $29.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $29.8 million in Q3 2024 and bottomed at $5.0 million in Q2 2020.
  • Average Shares Outstanding (Diluted Average) over 5 years is $19.6 million, with a median of $26.4 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Diluted Average): rose 0.09% in 2021, then skyrocketed 432.49% in 2022.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $5.0 million in 2020, then soared by 175.0% to $13.6 million in 2021, then skyrocketed by 93.84% to $26.4 million in 2022, then rose by 7.69% to $28.4 million in 2023, then grew by 5.02% to $29.8 million in 2024.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $29.8 million in Q3 2024, $29.7 million in Q2 2024, and $29.4 million in Q1 2024.